Hematologic Oncology | Specialty

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27th 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

FDA Approves Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma

February 27th 2021

The FDA has approved melphalan flufenamide for use in combination with dexamethasone in the treatment of select adult patients with relapsed/refractory multiple myeloma.

Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for Cancer Therapy

February 27th 2021

Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.

Relapsed/Refractory DLBCL Undergoes Rapid Evolution With CAR T-Cell Therapy, ADCs, and Bispecific Antibodies

February 26th 2021

High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and other novel agents, which have transformed the third-line setting, may offer alternative and more personalized second-line options in the coming years.

Raising the Standard Beyond Frontline R-CHOP in DLBCL

February 26th 2021

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL

February 26th 2021

Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.

Dr. Walters on the Safety Profile of Beti-Cel in Pediatric Transfusion-Dependent Beta-Thalassemia

February 26th 2021

Mark Walters, MD, discusses the safety profile of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent β-thalassemia, as reported in the phase 3 Northstar-2 and Northstar-3 trials.

Dr. Cortes on Future Research Directions With CPX-351 in AML

February 26th 2021

Jorge E. Cortes, MD, discusses future directions in the research of CPX-351 in patients with acute myeloid leukemia.

Treating R/R DLBCL With CAR-T: Current Barriers

February 26th 2021

CAR-T Treatment Options for R/R DLBCL

February 26th 2021

An Overview of Myeloproliferative Neoplasms

February 26th 2021

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

Individualizing Treatment Approaches in MPN

February 26th 2021

Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies

February 26th 2021

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

February 25th 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Dr. Ip on the Challenges of Treating Patients With Hematologic Malignancies and COVID-19

February 25th 2021

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25th 2021

Total body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric patients with high-risk acute lymphocytic leukemia compared with chemotherapy conditioning.

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

February 25th 2021

Bispecific Antibodies Propel the Relapsed/Refractory Myeloma Paradigm Further Ahead

February 25th 2021

Timothy M. Schmidt, MD, discusses the integration and utility of bispecific antibodies in relapsed/refractory multiple myeloma, as well as some of the most promising agents in clinical development.